Phenylephrine resinate particles having good auc
AssigneeMcNeil-PPC, Inc.
InventorsDer-Yang Lee, Cathy Gelotte
Life of this patent
Estimating the term…
Abstract
Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.
Claims15
A method of relieving nasal congestion, comprising administering a pharmaceutical formulation;
- said pharmaceutical formulation comprising a drug-resin complex comprising phenylephrine and a cation polystyrene sulfonate, wherein said cation polystyrene sulfonate comprises particle sizes of about 74 μm an to about 177 μm an prior to being combined with the phenylephrine.
A method of treating the symptoms of cold, influenza, allergies, or non-allergic rhinitis in a subject in need thereof comprising administering a pharmaceutical formulation;
- said pharmaceutical formulation comprising a drug-resin complex comprising phenylephrine and cation polystyrene sulfonate, wherein said cation polystyrene sulfonate comprises particle sizes of about 74 μm to about 177 μm.
A method of maintaining sustained bioavailability of phenylephrine in a subject, comprising administering a pharmaceutical formulation comprising a drug-resin complex comprising phenylephrine and a cation polystyrene sulfonate, wherein said cation polystyrene sulfonate comprises particle sizes of about 74 μm to about 177 μm, wherein a concentration of phenylephrine in plasma of the subject is at least about 20, about 40, about 60, about 80, about 100, about 120, about 140, about 160, about 180, or about 200, pg/mL at about 6, about 8, about 12, about 16, about 20, or about 24 hours after ingestion.
Dependencies are inferred from the claim text.